PB1878: CROSS-TRIAL ANALYSIS OF FIXED-DURATION IBRUTINIB (I) PLUS VENETOCLAX (V) VS FLUDARABINE (F), CYCLOPHOSPHAMIDE (C), AND RITUXIMAB (R) AS FIRST-LINE TREATMENT FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL). (23rd June 2022)

Record Type:: Journal Article
Title:: PB1878: CROSS-TRIAL ANALYSIS OF FIXED-DURATION IBRUTINIB (I) PLUS VENETOCLAX (V) VS FLUDARABINE (F), CYCLOPHOSPHAMIDE (C), AND RITUXIMAB (R) AS FIRST-LINE TREATMENT FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL). (23rd June 2022)
Main Title:: PB1878: CROSS-TRIAL ANALYSIS OF FIXED-DURATION IBRUTINIB (I) PLUS VENETOCLAX (V) VS FLUDARABINE (F), CYCLOPHOSPHAMIDE (C), AND RITUXIMAB (R) AS FIRST-LINE TREATMENT FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
Authors:: Barrientos, J. C.
Barr, P. M.
Mato, A. R.
Tam, C. S.
Ghia, P.
Moreno, C.
Kay, N. E.
Siddiqi, T.
Szafer-Glusman, E.
Zhou, C.
Neumayr, L.
Krigsfeld, G.
Wierda, W. G.
Shanafelt, T.
Abstract:
Is Part Of:: HemaSphere. Volume 6(2022)Supplement 3
Journal:: HemaSphere
Issue:: Volume 6(2022)Supplement 3
Issue Display:: Volume 6, Issue 3 (2022)
Year:: 2022
Volume:: 6
Issue:: 3
Issue Sort Value:: 2022-0006-0003-0000
Page Start:: 1758
Page End:: 1759
Publication Date:: 2022-06-23
Subjects:: Hematology -- Periodicals
616.15005
Journal URLs:: https://journals.lww.com/hemasphere/pages/default.aspx ↗
http://journals.lww.com/pages/default.aspx ↗
DOI:: 10.1097/01.HS9.0000850364.78915.d9 ↗
Languages:: English
ISSNs:: 2572-9241
Deposit Type:: Legaldeposit
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗
Physical Locations:: British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store
Ingest File:: 22683.xml